Evidence map›Paper›PMID 42356482›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway.

Qingmeng Yu, Ruiding Li, Zhengyu Li, Zhexin Wan, Kaikai Lv, Chongyang He, Jianfang Sun, Shubing Jia, Yijia Xu, Mingyi Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qingmeng YuSchool of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Ruiding LiSchool of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhengyu LiSchool of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhexin WanSchool of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Kaikai LvSchool of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China.
Chongyang HeSchool of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jianfang SunSchool of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shubing JiaSchool of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yijia XuSchool of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China.
Mingyi ZhaoSchool of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-tumordehydrocorydalinekey targetpancreatic cancersignal pathway

Identifiers

PMID42356482
PMCPMC13305804

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.